Introduction
============

Osteosarcoma is a very common osteoblast malignant tumor, which is prone to metastasis, especially lung tissue metastasis. It is highly malignant and the prognosis is not satisfactory ([@b1-ol-0-0-8307],[@b2-ol-0-0-8307]). Two to three out of one million individuals suffer from osteosarcoma each year, mainly male minors.

The treatment methods are becoming increasingly advanced and the prognosis of the patient has improved obviously since the 1870s ([@b3-ol-0-0-8307]). The currently used comprehensive treatment mode is preoperative chemotherapy-surgery-postoperative adjuvant chemotherapy and the highest 5-year survival rate of the patients has reached 80%. Nevertheless, there are patients who die after treatment failure ([@b4-ol-0-0-8307]). More research is needed to further understand the occurrence and the development of osteosarcoma, the pathogenesis of osteosarcoma, the development of the disease and the transfer mechanism to identify an ideal therapeutic target. The human cell division cycle gene 2 (*CDC2*), and its encoded cyclin CDC2 protein participates in regulating the transition of phase G2 into phase M in the interphase of mitosis ([@b5-ol-0-0-8307],[@b6-ol-0-0-8307]).

The pathogenesis and progression of cancer are related to the abnormal regulation of the cell cycle, and there is a high expression of CDC2 in many malignant tumors ([@b7-ol-0-0-8307]--[@b18-ol-0-0-8307]). However, there is less research on the expression level and clinical significance of CDC2 in osteosarcoma ([@b19-ol-0-0-8307]). In the present study, quantitative polymerase chain reaction (RT-PCR) was used to detect the expression of CDC2 in order to explore its clinical significance.

Materials and methods
=====================

### Clinical data

Specimens of cancer, paracancerous tissues and serum from 47 patients hospitalized at the Department of Orthopedics at The Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) from January, 2010 to January, 2015 and serum of 35 normal subjects were collected. The expression of *CDC2* was detected via PCR and the relationship between CDC2 expression and clinical features of patients with osteosarcoma was analyzed. The instruments and reagents used in this study are shown in [Table I](#tI-ol-0-0-8307){ref-type="table"}. The study was approved by the Ethics Committee of The Third Affiliated Hospital of Sun Yat-sen University, and the patient or their families signed informed consent.

### Detection of the CDC2 expression via RT-PCR

*CDC2* was extracted from tissues and serum in strict accordance with the instructions provided by Sigma-Aldrich (St. Louis, MO, USA) and Merck KGaA (Darmstadt, Germany), respectively, and the purity of RNA was expressed by the ratio of the absorbance value from 260 to 280 nm. Purity was satisfactory if the result was between 1.9 and 2.1; otherwise, the purification was repeated until it was up to the standard.

### RT-PCR

The experiment was conducted in strict accordance with the instructions of reverse transcription kits (Fermentas; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The PCR reaction system was measured as: 25 µl, *CDC2* annealing at 53°C, 25 cycles. Primer sequences are shown in [Table II](#tII-ol-0-0-8307){ref-type="table"}. For the statistical analysis, three parallel wells were set for all samples, and the average was taken. With U6 as the internal reference, the relative expression level of CDC2 was expressed as 2^−ΔΔCq^.

### Statistical analysis

SPSS 22.0 (IBM Corp., Armonk, NY, USA) was used for data analysis. The post hoc test was SNK test. Measurement data are presented as mean ± SD, and the analysis of variance was used for the comparison among groups. The t-test was used for the comparisons of CDC2 expression levels in specimens of cancer, paracancerous tissues and serum and the serum of 35 normal subjects, and the Chi-square test was used for the comparison of parametres including sex and age. The receiver operating characteristic (ROC) curve was drawn to assess the diagnosis value of serum CDC2 in patients with osteosarcoma and the relationship between CDC2 and osteosarcoma was analyzed via univariate and multivariate Cox regression analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression levels of CDC2 in tissues, cells and blood

CDC2 was highly expressed in cancer tissues, which was higher than that in paracancerous tissues (P\<0.05). The expression level in the blood of patients was higher than that in normal subjects (P\>0.05). The ROC curve analysis revealed that CDC2 had a high value in the diagnosis of osteosarcoma (AUC = 0.785, 95% CI = 0.729--0.834) ([Fig. 1](#f1-ol-0-0-8307){ref-type="fig"} and [Table IIIA and B](#tIII-ol-0-0-8307){ref-type="table"}).

### Clinical features of 47 patients with osteosarcoma

Of the 47 patients, 23 cases were osteoblastic; 13 were osteogenic; and 11, were fibroblastic osteosarcoma, respectively. In osteosarcoma cells, the expression level of CDC2 had no difference in terms of sex, age and occurrence site (P\>0.05). Osteosarcoma was divided into 3 levels: Parosteal (I), periosteal (II) and conventional osteosarcoma (III) according to the fourth edition of World Health Organization (WHO) bone tumor classification. The expression level of CDC2 was increased with the increase of level (P\<0.05). KPS was scored according to the evaluation standards of physical condition ([@b20-ol-0-0-8307]). The results showed that the expression level of *CDC2* was increasingly higher with the decrease of KPS score. The CDC2 expression level was closely associated with tumor diameter (P\<0.05). Finally, the expression level of CDC2 was increased with the increase of tumor lymph nodes metastasis (TNM) staging (P\<0.05) ([Table IV](#tIV-ol-0-0-8307){ref-type="table"}).

### Association of TNM staging and CDC2 level with survival rate of patients and its effect on prognosis

The median expression level of CDC2 in 47 patients with osteosarcoma was 2.49. Thus, the patients were divided into the high-expression CDC2 (\>2.49) and low-expression CDC2 (\<2.49) groups. The univariate and multivariate Cox regression analysis revealed that the increase of the TNM staging of osteosarcoma and the high expression of CDC2 were both risk factors affecting the prognosis of osteosarcoma patients (P\<0.05) ([Table V](#tV-ol-0-0-8307){ref-type="table"}).

Discussion
==========

Since the 21st century, it has been found ([@b21-ol-0-0-8307]) that the abnormal regulation of cell cycle is one of the most important causes of tumor. Researchers have concluded that cancer is a progressive disease that is caused by the destruction of the cell cycle regulation mechanism, and many genes are found to be involved in the cell cycle regulation, providing many important targets for the treatment of cancer ([@b22-ol-0-0-8307]).

*CDC* ([@b23-ol-0-0-8307]) is one of the genes that has been identified, the most important being *CDC2*, and the CDC2 kinase ([@b24-ol-0-0-8307]) encoded by it controls the beginning of the cell cycle and the transition from the G2 to the M phase. The cell cycle checkpoint regulates various cell regulators, thus completing the mitosis of cells. Previous findings have shown that the disruption of the function of the cell cycle checkpoint may lead to malignant differentiation of cells and produce tumors ([@b25-ol-0-0-8307]).

In the present study, the expression of CDC2 in cancer, paracancerous tissues and serum from patients and normal controls were detected via RT-PCR. The results showed that, there was a significant difference in the expression level of CDC2 between cancer and paracancerous tissues (P\<0.05), as well as the serum in patients and the normal control group (P\<0.05). It was also found that a high CDC2 expression may interfere with normal cell growth and differentiation and cause malignant cell proliferation, and the detection of CDC2 expression in serum may predict the occurrence of osteosarcoma. Leijen *et al* ([@b21-ol-0-0-8307]) found that the function of the tumor cell checkpoint is incomplete and can trigger an automatic interlocking feedback loop, which leads to further malignant cell growth. The expression level of CDC2 was closely associated with tumor diameter, WHO grading and KPS score, indicating that the expression level of CDC2 is closely associated with the occurrence and development of osteosarcoma. Chae *et al* ([@b26-ol-0-0-8307]) reported that the expression of CDC2 is significantly different between benign and malignant breast lesions, and the increase of CDC2 levels is associated with tumor invasiveness. The results in the present study also showed that the expression level of CDC2 was associated with the TNM staging of osteosarcoma (P\<0.05), suggesting that a high expression of CDC2 in osteosarcoma may promote the development of osteosarcoma, and the detection of CDC2 expression in serum may predict the development of osteosarcoma. Yang *et al* ([@b27-ol-0-0-8307]) found that CDC2 is associated with squamous cell carcinoma of the larynx. The multivariate Cox regression analysis of the prognosis of osteosarcoma patients revealed that the expression level of CDC2 was a risk factor affecting the prognosis of patients with osteosarcoma (P\<0.05), making it possible to predict the prognosis of osteosarcoma by detecting the CDC2 expression level in serum. Jansen *et al* ([@b18-ol-0-0-8307]) found that *CDC2* plays a crucial role in G2 cell cycle progression and cell proliferation, and CDC2 may be considered as a prognostic marker for metastatic breast cancer.

Since no relevant reports are currently available to confirm the clinical significance of CDC2 expression in osteosarcoma, and the sample size was small in this study with a lack of representativeness, a larger number of samples are needed to confirm the findings. In this study, whether patients received chemotherapy and radiotherapy was not recorded; thus, further verification is needed in future research.

Collectively, CDC2 is highly expressed in osteosarcoma tumor cells. A high expression of CDC2 may be involved in the process of tumor development and progression, which leads to disordered mitosis and malignant proliferation of cells. The detection of CDC2 expression in serum may predict the occurrence, development and prognosis of osteosarcoma.
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###### 

Instruments and reagents.

  Instruments and reagents    Manufacturer
  --------------------------- -----------------------------------------------------------------------
  PCR instrument              Applied Biosystems; Thermo Fisher Scientific, Inc. (Waltham, MA, USA)
  Spectrophotometer SMA5000   Merinton Instrument, Inc. (Ann Arbor, MI, USA)
  Reverse transcription kit   Fermentas; Thermo Fisher Scientific, Inc.
  U6 internal reference       Guangzhou Shangeng Biological Technology Co., Ltd. (Guangzhou, China)
  100 bp DNA Marker           Tiangen Biotech Co., Ltd. (Beijing, China)
  2X Taq PCR MasterMix        Tiangen Biotech Co., Ltd.
  TRIzol                      Tiangen Biotech Co., Ltd.
  DEPC                        Sigma Sigma-Aldrich; Merck KGaA (Darmstadt, Germany)

PCR, polymerase chain reaction; DEPC, diethyl pyrocarbonate.

###### 

Primer sequences.

  Primer   U6 internal reference        CDC2
  -------- ---------------------------- ------------------------------
  F        5′-CTCGCTTCGGCAGCACA-3       5′-TACCTATGGAGTTGTGTATAA-3′
  R        5′-AACGCTTCACGAATTTGCGT-3′   5'′-ATTCCACTTCTGGCCACACTT-3′

F, forward; R, reverse; CDC2, cell division cycle gene 2.

###### 

Expression levels of CDC2 in tissues and blood.

  A, Tissue                              
  --------------- ---------------------- ---------
  Cancer tissue   Paracancerous tissue   P-value
  2.31±0.306      0.91±0.251             0.013
                                         
  **B, Blood**                           
                                         
  Patient         Normal subject         P-value
  1.58±0.149      0.67±0.136             0.024

CDC2, cell division cycle gene 2.

###### 

Clinical characteristics of 447 patients with osteosarcoma.

  Item                          No.   CDC2 expression level   P-value
  ----------------------------- ----- ----------------------- ---------
  Sex                                                         
    Male                        31    2.38±0.317              0.685
    Female                      16    2.24±0.305              
  Age (years)                                                 
    \<12                        25    2.31±0.313              0.314
    ≥12                         22    1.91±0.206              
  Histological subtypes                                       
    Osteoblastic osteosarcoma   23    2.11±0.331              0.412
    Osteogenic osteosarcoma     13    1.98±0.285              
    Fibroblastic osteosarcoma   11    2.06±0.446              
  KPS score                                                   
    \<70                        30    3.01±0.363              0.032
    ≥70                         17    1.81±0.106              
  Tumor location                                              
    Upper limb bone             9     2.43±0.278              0.647
    Lower limb bone             38    2.31±0.306              
  Tumor size (cm)                                             
    \<10                        36    2.84±0.267              0.042
    ≥10                         11    1.94±0.348              
  WHO classification                                          
      I                         15    1.57±0.124              
      II                        24    2.79±0.217              0.039
      III                       8     1.97±0.135              
  TNM staging                                                 
    I/II                        35    1.65±0.152              0.035
    III/IV                      12    2.87±0.225              
  Pathological fracture                                       
    Yes                         11    2.48±0.165              0.752
    No                          36    2.74±0.274              

*CDC2*, cell division cycle gene 2, TNM, tumor lymph nodes metastasis; WHO, World Health Organization.

###### 

Univariate and multivariate analysis.

  Variables                             Univariate HR (95%CI)   Multivariate P-value   HR (95%CI)               P-value
  ------------------------------------- ----------------------- ---------------------- ------------------------ ---------
  CDC2 (low vs. high)                   1.647 (1.122--2.896)    0.009                  1.969 (0.9505--4.0765)   0.012
  Age (\<12 vs. ≥12 years)              1.014 (0.999--1.029)    0.062                                           
  Sex (male vs. female)                 0.819                                                                   
  (0.277--2.424)                        0.788                                                                   
  Diameter of tumor (\<10 vs. ≥10 cm)   0.812                                                                   
  (0.357--1.847)                        0.682                                                                   
  Tumor site                            2.2611                                                                  
  (Upper vs. lower limb bone)                                                                                   
  (0.9821--147.3)                       0.052                                                                   
  TNM staging                           3.064                                                                   
  (1.282--7.323)                        0.028                   1.268 (0.918--2.471)   0.041                    

*CDC2*, cell division cycle gene 2, TNM, tumor lymph nodes metastasis.
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